COMP <GO>
ICCC vs UNH // REVENUE GROWTH (YOY)
ImmuCell Corporation (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ICCC 5
— UNH 7
▲ REVENUE GROWTH (YOY) LEADER: ICCC
LAST: $10.56 (+2.92%) • MKT CAP: $95.9M
revenue-growth
4.30%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
revenue-growth
3.33%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ICCC VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ICCC | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.40% | 88.31% | -46.91 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.20% | 12.38% | -8.18 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 35.9x | 15.3x | +20.63 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 1.31% | 6.25% | -4.94 | UNH | /fcf-yield <GO> |
| Operating Margin | 6.00% | 5.32% | +0.68 | ICCC | /operating-margins <GO> |
| Net Profit Margin | -3.80% | 3.53% | -7.33 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 4.30% | 3.33% | +0.97 | ICCC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.28 | 3.09 | +1.19 | ICCC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ICCC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.0 | 55.1 | +1.90 | ICCC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $95.9M | $359.43B | -$359.34B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ICCC REV | UNH REV | ICCC GROSS % | UNH GROSS % | ICCC FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $27.6M | $447.57B | 41.4% | 88.7% | $1.2M | $16.07B |
| FY 2024 | $26.5M | $400.28B | 30.0% | 88.3% | -$107.8K | $20.70B |
| FY 2023 | $17.5M | $371.62B | — | 89.6% | -$4.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ICCC // BETA —
UNH // BETA 0.33